Clinical and Economic Aspects of KRAS Mutational Status as Predictor for Epidermal Growth Factor Receptor Inhibitor Therapy in Metastatic Colorectal Cancer Patients

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Oncology

• Publication date

  2012-01-13

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.1159/000334919PMID 22248908
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Global cancer statistics

  2011cited by this paper
• Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients

  2011cited by this paper
• Circulating tumor cells in metastatic colorectal cancer: efficacy and feasibility of different enrichment methods.

  2010cited by this paper
• EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer.

  2010cited by this paper
• The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development.

  2010cited by this paper
• Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

  2009cited by this paper
• Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.

  2009cited by this paper
• Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer

  2009cited by this paper
• Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors.

  2009cited by this paper
• Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

  2009cited by this paper
• Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.

  2009cited by this paper
• K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

  2008cited by this paper
• KRAS mutations predict response to EGFR inhibitors.

  2008cited by this paper
• KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.

  2008cited by this paper
• KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

  2008cited by this paper
• Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

  2008cited by this paper
• Cetuximab for the treatment of colorectal cancer.

  2007cited by this paper
• Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

  2007cited by this paper
• Cancer Statistics, 2007

  2007cited by this paper
• Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer

  2007cited by this paper
• Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

  2007cited by this paper
• REporting recommendations for tumor MARKer prognostic studies (REMARK)

  2006cited by this paper
• KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

  2006cited by this paper
• Novel approaches to treatment of advanced colorectal cancer with anti‐EGFR monoclonal antibodies

  2006cited by this paper
• REporting recommendations for tumor MARKer prognostic studies (REMARK)

  2005cited by this paper
• Global Cancer Statistics, 2002

  2005cited by this paper
• Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

  2005cited by this paper
• Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.

  2005cited by this paper
• Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

  2004cited by this paper
• Cetuximab in the treatment of colorectal cancer.

  2004cited by this paper
• The price tag on progress--chemotherapy for colorectal cancer.

  2004cited by this paper
• Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.

  2002cited by this paper
• Expression of the Tyrosine Kinase Activity Growth Factor Receptors (EGFR, ERB B2, ERB B3) in Colorectal Adenocarcinomas and Adenomas

  2000cited by this paper
• EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma.

  1998cited by this paper
• Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study.

  1998cited by this paper
• EGF, TGF-a, and EGF-R in Human Colorectal Adenocarcinoma

  1998cited by this paper
• A detailed analysis of K‐ras point mutations in relation to tumor progression and survival in colorectal cancer patients

  1996cited by this paper

• Evaluating the quality of the economic evidence in colorectal cancer genomics studies.

  2022cites this paper
• Epidermal Growth Factor Receptor Inhibitor Treatment Timing does not Impact Survival in Stage 4 Colon Cancer Treatment: A Retrospective Study

  2022cites this paper
• Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: a retrospective analysis in Chinese postmenopausal women

  2019cites this paper
• Economic Value of Pharmacogenetic Testing for Cancer Drugs with Clinically Relevant Drug-Gene Associations: A Systematic Literature Review.

  2019cites this paper
• Mps1 is associated with the BRAFV600E mutation and predicts poor outcome in patients with colorectal cancer

  2019cites this paper
• The Economics of Personalized Therapy in Metastatic Colorectal Cancer

  2016cites this paper
• Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status

  2015cites this paper
• Cost Considerations in the Evaluation and Treatment of Colorectal Cancer

  2015cites this paper
• Co-Expression of HER Family Members in Patients with Dukes’ C and D Colon Cancer and Their Impacts on Patient Prognosis and Survival

  2014cites this paper
• Pharmacogenomics of cetuximab in metastatic colorectal carcinoma.

  2014cites this paper
• Targeted therapy in metastatic colorectal cancer -- an example of personalised medicine in action.

  2013cites this paper
• The relevance of BRAF and extended RAS mutational analyses for metastatic colorectal cancer patients

  2013cites this paper
• Overcoming implementation challenges of personalized cancer therapy

  2012cites this paper